Dose Sales

Some comment has been made about the 22% not being so good.

These are the 1/4 dose sales increases against the previous year. Note that for the last year the 3rd and 4th 1/4 had 26% & 33% increases over the previous year for US sales.

So, the 'drop' from 28% to 22% needs to be viewed in perspective of two very good 1/4 last year.
22% YTD is a good number in my book. However it appears that anyone shorting the stock would highlight this as a negative. As always we need to look a little deeper than the headline data.

	Column 1	Column 2	Column 3	Column 4	Column 5
1		2014.1	2014.2	2014.3	2014.4
2	USA	6.6	23.7	25.8	33
3	EU	5.1	5.9	3.6	16.7
4	Asia	10.2	18.2	8.6	11.7
5	total	4.1	18.7	18.2	27.1

Always happy to discuss hard data.

I changed my sentiment last week from hold to buy, and happy with that as current.